Repare Therapeutics Inc. (RPTX)
Largest Insider Buys in Sector
RPTX Stock Price History Chart
RPTX Stock Performance
About Repare Therapeutics Inc.
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related …
Insider Activity of Repare Therapeutics Inc.
Over the last 12 months, insiders at Repare Therapeutics Inc. have bought $0 and sold $101,063 worth of Repare Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Repare Therapeutics Inc. have bought $40.13M and sold $25.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 295,745 shares for transaction amount of $1.59M was made by BVF PARTNERS L P/IL (10 percent owner) on 2023‑11‑16.
List of Insider Buy and Sell Transactions, Repare Therapeutics Inc.
| 2024-04-01 | Sale | EVP, CHIEF MEDICAL OFFICER | 300 0.0007% | $4.66 | $1,398 | -28.09% | ||
| 2024-04-01 | Sale | PRESIDENT AND CEO | 2,491 0.0058% | $4.63 | $11,533 | -28.09% | ||
| 2024-04-01 | Sale | EVP, CHIEF SCIENTIFIC OFFICER | 410 0.001% | $4.66 | $1,911 | -28.09% | ||
| 2024-04-01 | Sale | EVP, CHIEF FINANCIAL OFFICER | 789 0.0018% | $4.61 | $3,637 | -28.09% | ||
| 2024-03-28 | Sale | EVP, CHIEF MEDICAL OFFICER | 500 0.0012% | $4.64 | $2,320 | -28.13% | ||
| 2024-03-28 | Sale | PRESIDENT AND CEO | 2,650 0.0062% | $4.62 | $12,243 | -28.13% | ||
| 2024-03-28 | Sale | EVP, CHIEF SCIENTIFIC OFFICER | 450 0.0011% | $4.64 | $2,088 | -28.13% | ||
| 2024-03-28 | Sale | EVP, CHIEF FINANCIAL OFFICER | 825 0.0019% | $4.62 | $3,812 | -28.13% | ||
| 2024-03-27 | Sale | EVP, CHIEF MEDICAL OFFICER | 500 0.0012% | $4.62 | $2,310 | -27.41% | ||
| 2024-03-27 | Sale | PRESIDENT AND CEO | 2,650 0.0062% | $4.63 | $12,270 | -27.41% | ||
| 2024-03-27 | Sale | EVP, CHIEF SCIENTIFIC OFFICER | 450 0.0011% | $4.62 | $2,079 | -27.41% | ||
| 2024-03-27 | Sale | EVP, CHIEF FINANCIAL OFFICER | 825 0.0019% | $4.62 | $3,812 | -27.41% | ||
| 2024-03-26 | Sale | EVP, CHIEF MEDICAL OFFICER | 500 0.0012% | $4.60 | $2,300 | -25.06% | ||
| 2024-03-26 | Sale | PRESIDENT AND CEO | 2,650 0.0064% | $4.64 | $12,296 | -25.06% | ||
| 2024-03-26 | Sale | EVP, CHIEF SCIENTIFIC OFFICER | 450 0.0011% | $4.61 | $2,075 | -25.06% | ||
| 2024-03-26 | Sale | EVP, CHIEF FINANCIAL OFFICER | 825 0.002% | $4.60 | $3,795 | -25.06% | ||
| 2024-03-25 | Sale | EVP, CHIEF MEDICAL OFFICER | 500 0.0012% | $4.78 | $2,390 | -28.57% | ||
| 2024-03-25 | Sale | PRESIDENT AND CEO | 2,650 0.0063% | $4.79 | $12,694 | -28.57% | ||
| 2024-03-25 | Sale | EVP, CHIEF SCIENTIFIC OFFICER | 450 0.0011% | $4.78 | $2,151 | -28.57% | ||
| 2024-03-25 | Sale | EVP, CHIEF FINANCIAL OFFICER | 825 0.002% | $4.79 | $3,952 | -28.57% |
Insider Historical Profitability
| Segal Lloyd Mitchell | PRESIDENT AND CEO | 107558 0.253% | $1.36 | 1 | 13 | <0.0001% |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER | 44775 0.1053% | $1.36 | 1 | 5 | <0.0001% |
| BVF PARTNERS L P/IL | 10 percent owner | 5309432 12.4896% | $1.36 | 4 | 0 | <0.0001% |
| LAMPERT MARK N | 4443423 10.4525% | $1.36 | 3 | 0 | +11.32% | |
| GADICKE ANSBERT | 10 percent owner | 3882485 9.133% | $1.36 | 1 | 30 | <0.0001% |
Institutional Investor Ownership
| Bvf Inc Il | $48.67M | 24.35 | 10.33M | 0% | +$0 | 0.36 | |
| OrbiMed | $15.65M | 7.83 | 3.32M | 0% | +$0 | 0.12 | |
| Blue Owl Capital Holdings Lp | $14.71M | 7.36 | 3.12M | 0% | +$0 | 1.23 | |
| ARK Investment Management LLC | $12.73M | 6.37 | 2.7M | -4.17% | -$554,729.76 | 0.04 | |
| Deep Track Capital Lp | $12.64M | 6.32 | 2.68M | -10.3% | -$1.45M | 0.06 |